Discover 2,591 paid clinical trials in Illinois. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Illinois offers various clinical research options, including those for healthy volunteers interested in paid studies, as well as for individuals with specific health conditions. Leading research centers in Chicago, Plainfield, and Springfield are actively seeking participants, providing access to innovative treatments and personalized care.
Filter
1
Filter results
Results: 2,591
A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease
for
Sickle Cell Disease
Location: Chicago IL
Sponsor: EpiDestiny, Inc.
Sex: All
Age: 18+
Code: NCT04055818
Phase 1, Recruiting
Dysbiosis & Long COVID
for
COVID-19
Location: Chicago IL
Sponsor: University of Chicago
Sex: All
Age: 18 - 70+
Code: NCT06825819
Recruiting
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Location: South Orange NJ, Dover NJ, Bala-Cynwyd PA,
Sponsor: Bausch & Lomb Incorporated
Sex: All
Age: 22+
Code: NCT06060041
Recruiting
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
for
Myelodysplastic Syndrome
Location: Boston MA, Lebanon NH, Stony Brook NY, Long Branch NJ,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06577441
Phase 2, Recruiting
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
for
Metastatic Castration-Resistant Prostate Cancer
Location: Boston MA, Miami FL, Tampa FL, Chicago IL, Omaha NE
Sponsor: AstraZeneca
Sex: Male
Age: 18+
Code: NCT06879041
Phase 1, Recruiting
An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome
for
Lennox Gastaut Syndrome
Location: New York NY, Marlboro NJ, Philadelphia PA,
Sponsor: Epygenix
Sex: All
Age: 2 - 55
Code: NCT05066217
Phase 3, Recruiting
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma